Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
-Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress
-83% overall survival at two years vs. 34.3% OS from institutional database
-17.95 months median progression-free survival vs. 5.8 months PFS in historical group
We are building a pipeline of compelling investigational therapies targeting indications for which we believe gene therapy can have the greatest impact in patients with rare genetic diseases.
Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT).
To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China